Washington, USA – A clinical trial by US Drug Company Moderna revealed that the coronavirus vaccine produced was 95.4 per cent effective.

Exciting development in coronavirus vaccine! It was 95.4 percent successful.
Following BioNTech came promising news from the American biotechnology company Moderna about the vaccine developed against the new type of coronavirus (Covid-19).

Moderna explained that the first data from the study, which is still ongoing, showed that its vaccine was 95.4 percent effective. The company’s Chairman, Dr Stephen Hoge, called the data “a truly significant milestone.”

“It should give us hope that a vaccine can stop the epidemic and hopefully we will return to our old lives,” Hoge said, adding that it was “very comforting” to have similar results from two different companies. the phrase ” used.

Stephen Hoge said: “Moderna alone cannot solve this problem. Many vaccines will be needed to meet global demand., “he said.

Moderna’s vaccine, produced in the United States in conjunction with the National Institutes of health, is currently being tested on 30 thousand people who have been vaccinated or given a placebo.

A potential vaccine developed by the German biotech company BioNTech, co-founded by American pharmaceutical company Pfizer and Turkish scientist Prof Dr Uğur Şahin and his wife Dr Özlem Türeci, against Covid-19 was reported to be more than 90 percent effective against the virus.

It was announced that the vaccine candidate named bnt162b1 was tested on 43,538 people in 6 countries, and no serious safety concerns have been raised in the trials so far.

As countries around the world compete to sign contracts for millions of vaccine doses, BioNTech has previously announced plans to produce 100 million more vaccines globally by the end of 2020 and about 1.3 billion more by the end of 2021.

Pfizer and BioNTech had already signed preliminary agreements with the US, EU, UK, Canada and Japan to supply the vaccine. The companies had signed a $ 1.95 billion contract to provide the U.S. government with 100 million doses of the vaccine starting this year.

The EU Commission announced yesterday that the Commission will soon sign contracts with these companies to receive up to 300 million doses of the vaccine.

The EU has previously signed contracts to buy vaccines with pharmaceutical companies Johnson and Johnson, AstraZeneca and Sanofi-GSK, in addition, CureVac, BioNTech-Pfizer and Moderna announced successful vaccine acquisition talks.